Therapeutic Asset Ratings
227 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Ribociclib
Acute Lymphoblastic Leukemia
Dana-Farber Cancer Institute
P1
CC
(43)
Ricolinostat
B-Cell Chronic Lymphocytic Leukemia
Dana-Farber Cancer Institute
P1
CC
(43)
Rqnestin
Anaplastic Oligodendroglioma
Dana-Farber Cancer Institute
P1
CC
(43)
Rqnestin
Astrocytic Tumor
Dana-Farber Cancer Institute
P1
CC
(43)
Rqnestin
Ependymoma
Dana-Farber Cancer Institute
P1
CC
(43)
Rqnestin
Ganglioglioma
Dana-Farber Cancer Institute
P1
CC
(43)
Rqnestin
Anaplastic Astrocytoma
Dana-Farber Cancer Institute
P1
CC
(43)
Rqnestin
Brain Glioma
Dana-Farber Cancer Institute
P1
CC
(43)
Rqnestin
Oligoastrocytoma
Dana-Farber Cancer Institute
P1
CC
(43)
Rqnestin
Oligodendroglioma
Dana-Farber Cancer Institute
P1
CC
(43)
Rqnestin
Pilocytic Astrocytoma
Dana-Farber Cancer Institute
P1
CC
(43)
Selinexor
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Dana-Farber Cancer Institute
P1
CC
(43)
Selinexor
Refractory Biphenotypic Leukemia
Dana-Farber Cancer Institute
P1
CC
(43)
Selinexor
Refractory Mixed Lineage Leukemia
Dana-Farber Cancer Institute
P1
CC
(43)
Selinexor
Acute Biphenotypic Leukemia
Dana-Farber Cancer Institute
P1
CC
(43)
Tazemetostat
Early Stage Triple-Negative Breast Carcinoma
Dana-Farber Cancer Institute
P1
CC
(43)
Thiotepa
Myeloid Leukemia
Dana-Farber Cancer Institute
P1
CC
(43)
Treg-Enriched Donor Cell
Graft Versus Host Disease
Dana-Farber Cancer Institute
P1
CC
(43)
Treg-Enriched Donor Cell
Acute Myeloid Leukemia
Dana-Farber Cancer Institute
P1
CC
(43)
Treg-Enriched Donor Cell
Myeloid Leukemia
Dana-Farber Cancer Institute
P1
CC
(43)
Treg-Enriched Donor Cell
Disease Related To Hematopoietic Stem Cell Transplant
Dana-Farber Cancer Institute
P1
CC
(43)
Venetoclax
Breast Neoplasm
Dana-Farber Cancer Institute
P1
CC
(43)
Venetoclax
Early Stage Triple-Negative Breast Carcinoma
Dana-Farber Cancer Institute
P1
CC
(43)
Zoladex
Acute Lymphoblastic Leukemia ALL
Dana-Farber Cancer Institute
P1
CC
(43)
Ibrutinib
Refractory Malignant Neoplasm
Dana-Farber Cancer Institute
P1/2
CC
(43)
Showing 151 to 175 of 227 assets
Previous
Page 7 of 10
Next